Sufficient Regional Lymph Node Examination for Staging Adenocarcinoma of the Appendix
CONCLUSIONS: In appendix adenocarcinoma, examining a minimum of ten LNs was necessary to minimize the risk of missing LNP disease and was associated with improved overall survival rates. To mitigate the risk of misclassification, an adequate number of regional LNs must be assessed to determine LN status.PMID:38153641 | DOI:10.1245/s10434-023-14683-x (Source: Ann Oncol)
Source: Ann Oncol - December 28, 2023 Category: Cancer & Oncology Authors: Felipe Lopez-Ramirez Armando Sardi Mary Caitlin King Andrei Nikiforchin Luis Felipe Falla-Zuniga Philipp Barakat Carol Nieroda Vadim Gushchin Source Type: research

Biopsychosocial Late Effects After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal and Appendiceal Cancer: A National Prospective Cohort Study
CONCLUSION: Biopsychosocial LEs were prevalent. The QoL of patients reporting LEs in the worst severity categories was negatively impacted. Screening and treatment for these LEs should be a focus in cancer survivor follow-up.PMID:38127212 | DOI:10.1245/s10434-023-14618-6 (Source: Ann Oncol)
Source: Ann Oncol - December 21, 2023 Category: Cancer & Oncology Authors: Rogini Balachandran Henriette Vind Thaysen Peter Christensen Robert Zachariae Lene Hjerrild Iversen Source Type: research

Biopsychosocial Late Effects After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal and Appendiceal Cancer: A National Prospective Cohort Study
CONCLUSION: Biopsychosocial LEs were prevalent. The QoL of patients reporting LEs in the worst severity categories was negatively impacted. Screening and treatment for these LEs should be a focus in cancer survivor follow-up.PMID:38127212 | DOI:10.1245/s10434-023-14618-6 (Source: Ann Oncol)
Source: Ann Oncol - December 21, 2023 Category: Cancer & Oncology Authors: Rogini Balachandran Henriette Vind Thaysen Peter Christensen Robert Zachariae Lene Hjerrild Iversen Source Type: research

ASO Visual Abstract: Biopsychosocial Late Effects  After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal and Appendiceal Cancer: A National Prospective Cohort Study
Ann Surg Oncol. 2023 Dec 19. doi: 10.1245/s10434-023-14761-0. Online ahead of print.NO ABSTRACTPMID:38112887 | DOI:10.1245/s10434-023-14761-0 (Source: Ann Oncol)
Source: Ann Oncol - December 19, 2023 Category: Cancer & Oncology Authors: Rogini Balachandran Henriette Vind Thaysen Peter Christensen Robert Zachariae Lene Hjerrild Iversen Source Type: research

ASO Visual Abstract: Biopsychosocial Late Effects  After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal and Appendiceal Cancer: A National Prospective Cohort Study
Ann Surg Oncol. 2023 Dec 19. doi: 10.1245/s10434-023-14761-0. Online ahead of print.NO ABSTRACTPMID:38112887 | DOI:10.1245/s10434-023-14761-0 (Source: Ann Oncol)
Source: Ann Oncol - December 19, 2023 Category: Cancer & Oncology Authors: Rogini Balachandran Henriette Vind Thaysen Peter Christensen Robert Zachariae Lene Hjerrild Iversen Source Type: research

ASO Author Reflections: Biopsychosocial Late Effects are Frequent and Negatively Impact Quality of Life Following Curatively Intended Surgery for Colorectal and Appendiceal Cancer with Peritoneal Metastases
Ann Surg Oncol. 2023 Dec 10. doi: 10.1245/s10434-023-14727-2. Online ahead of print.NO ABSTRACTPMID:38071710 | DOI:10.1245/s10434-023-14727-2 (Source: Ann Oncol)
Source: Ann Oncol - December 10, 2023 Category: Cancer & Oncology Authors: Rogini Balachandran Henriette Vind Thaysen Peter Christensen Robert Zachariae Lene Hjerrild Iversen Source Type: research

ASO Author Reflections: Leave No Stone Unturned-Confidently Ruling Out Metastatic Lymph Node Disease in Appendix Cancer
Ann Surg Oncol. 2023 Dec 10. doi: 10.1245/s10434-023-14773-w. Online ahead of print.NO ABSTRACTPMID:38071701 | DOI:10.1245/s10434-023-14773-w (Source: Ann Oncol)
Source: Ann Oncol - December 10, 2023 Category: Cancer & Oncology Authors: Felipe Lopez-Ramirez Mary Caitlin King Armando Sardi Vadim Gushchin Source Type: research

Letter to the Editor of Annals of Surgical Oncology Concerning "Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA"
Ann Surg Oncol. 2023 Nov 16. doi: 10.1245/s10434-023-14595-w. Online ahead of print.NO ABSTRACTPMID:37971615 | DOI:10.1245/s10434-023-14595-w (Source: Ann Oncol)
Source: Ann Oncol - November 16, 2023 Category: Cancer & Oncology Authors: Chong-Chi Chiu Source Type: research

Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: The Oncologist - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research

Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research

Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: The Oncologist - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research

Prediction of Early Recurrence Following CRS/HIPEC in Patients With Disseminated Appendiceal Cancer
CONCLUSIONS: In this multi-institutional cohort of dAC patients that underwent CRS ± HIPEC, AutoML performed well in predicting patients with ER. Variables suggestive of poor tumor biology were the most influential for prediction. Our work provides a framework for identifying patients with ER that might benefit from shorter interval surveillance early after surgery.PMID:37666090 | DOI:10.1016/j.jss.2023.06.054 (Source: Cancer Control)
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Gopika SenthilKumar Jennifer Merrill Ugwuji N Maduekwe Jordan M Cloyd Keith Fournier Daniel E Abbott Nabeel Zafar Sameer Patel Fabian Johnston Sean Dineen Joel Baumgartner Travis E Grotz Shishir K Maithel Mustafa Raoof Laura Lambert Ryan Hendrix Anai N Ko Source Type: research

Prediction of Early Recurrence Following CRS/HIPEC in Patients With Disseminated Appendiceal Cancer
This study aims to: (1) characterize patients with dAC that are at risk for recurrence within 2 y following of CRS  ± HIPEC (early recurrence; ER), (2) utilize automated machine learning (AutoML) to predict at-risk patients, and (3) identifying factors that are influential for prediction. (Source: Journal of Surgical Research)
Source: Journal of Surgical Research - September 2, 2023 Category: Surgery Authors: Gopika SenthilKumar, Jennifer Merrill, Ugwuji N. Maduekwe, Jordan M. Cloyd, Keith Fournier, Daniel E. Abbott, Nabeel Zafar, Sameer Patel, Fabian Johnston, Sean Dineen, Joel Baumgartner, Travis E. Grotz, Shishir K. Maithel, Mustafa Raoof, Laura Lambert, Ry Tags: Surgical Oncology Source Type: research

Patterns of Recurrence in Appendix Cancer After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
CONCLUSIONS: After complete CRS/HIPEC, IPR was the predominant pattern in all AC histologies and occurred later. Post-recurrence survival after IPR was longer. Knowing AC recurrence patterns can help to understand its biology and plan follow-up and post-relapse management.PMID:37633853 | DOI:10.1245/s10434-023-14145-4 (Source: Ann Oncol)
Source: Ann Oncol - August 26, 2023 Category: Cancer & Oncology Authors: Andrei Nikiforchin Armando Sardi Mary Caitlin King Ekaterina Baron Felipe Lopez-Ramirez Luis Felipe Falla-Zuniga Philipp Barakat Sergei Iugai Kathleen Pawlikowski Carol Nieroda Vadim Gushchin Source Type: research

ASO Author Reflections: Let's Redouble Efforts to Stop Peritoneal Recurrence in All Types of Appendix Cancer
Ann Surg Oncol. 2023 Aug 25. doi: 10.1245/s10434-023-14160-5. Online ahead of print.NO ABSTRACTPMID:37624519 | DOI:10.1245/s10434-023-14160-5 (Source: Ann Oncol)
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Andrei Nikiforchin Armando Sardi Mary Caitlin King Vadim Gushchin Source Type: research